New Primer Highlights Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards Read more about New Primer Highlights Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Talking Points on ICER and NEWDIGS Gene Therapy White Paper (April 2024) Read more about Talking Points on ICER and NEWDIGS Gene Therapy White Paper (April 2024)
Acknowledging the Challenges in Gene Therapy: Perspectives on ICER's White Paper Read more about Acknowledging the Challenges in Gene Therapy: Perspectives on ICER's White Paper
It’s time to stop talking past each other on drug pricing Read more about It’s time to stop talking past each other on drug pricing
NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Read more about NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds Read more about Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications Read more about Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis Read more about Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025 Read more about NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025
NPC Submits Comments to CMS on Proposed Changes to Medicare Programs Read more about NPC Submits Comments to CMS on Proposed Changes to Medicare Programs